# SACTION 01 (NCT05319574)

> SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05319574
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sun Yat-sen University
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: SBRT; Tislelizumab
- Enrollment: 46
- Primary outcome: Major Pathological Response (MPR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=saction-01-nct05319574